{"id":615,"date":"2026-05-18T15:59:08","date_gmt":"2026-05-18T15:59:08","guid":{"rendered":"https:\/\/bindlab.cyceron.fr\/bindlab\/?page_id=615"},"modified":"2026-07-01T15:44:21","modified_gmt":"2026-07-01T15:44:21","slug":"micid","status":"publish","type":"page","link":"https:\/\/bind-lab.fr\/?page_id=615","title":{"rendered":"MICID"},"content":{"rendered":"\n
\n

Molecular imaging in chronic inflammatory diseases<\/em><\/h4>\n\n\n\n
Funded by Agence Nationale de la Recherche<\/strong><\/h5>\n<\/div>\n\n\n\n
\n\n\n\n
<\/div>\n\n\n\n
\n
\n

Context and challenges<\/h4>\n\n\n\n

Early diagnosis of chronic inflammation for one can improve patient care by introducing therapies at a reversible stage of the diseases. It can also be employed as a prognostic marker or to monitor therapies. Circulating biomarkers, although extremely valuable, lack specificity or sensitivity, especially for detecting and localizing low grade chronic inflammation. VCAM-1 is minimally expressed in healthy vessels but overexpressed throughout all the duration of the inflammatory process. The LRB laboratory has developed a single domain antibody (sdAb)-based imaging agent for the nuclear imaging of VCAM-1 (cAbVCAM1-5), currently the first anti VCAM-1 imaging agent to have reached phase I clinical trial (NCT04483167), as a vulnerable atherosclerotic plaque tracer. <\/p>\n\n\n\n

<\/div>\n\n\n\n

Objective<\/h4>\n\n\n\n

The aim of the present project is to further evaluate cAbVCAM1-5 diagnostic and prognostic value in preclinical models of spondyloarthritis, myocardial infarction, and neuroinflammation in order to pave the way of future clinical evaluations. In addition, cAbVCAM1-5 potency for MRI and MPI is going to be evaluated as an alternative to nuclear imaging.<\/p>\n\n\n\n

\n